Shawn Pelletier, MD
Transplant Surgery · Charlottesville, VANPI 1972604882
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $815 of the $1,092 with a category attached, or 74.6%. 4 manufacturers reported payments, led by Davol Inc. at 44.0% of the total. Reporting peaked in 2023 at $486 and has fallen 74.2% since, to $125 in 2025.
Across 7 payments — averaging $156.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Davol Inc.$480
- Organ Recovery Systems, Inc.$420
- Mirum Pharmaceuticals, Inc.$125
- Medtronic$66
Across 32 payments — averaging $29,400 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Organ Recovery Systems, Inc.$839K
- Transmedics, Inc.$102K
What the payments were for
- Travel & lodging$27725%
- Food & beverage$81575%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Davol Inc. | 4 | $480 |
| Organ Recovery Systems, Inc. | 1 | $420 |
| Mirum Pharmaceuticals, Inc. | 1 | $125 |
| Medtronic | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Phasix Mesh$433
- Livmarli$125
How this compares
Too few transplant surgery providers in Virginiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Entecavir | 11 | $782 |
| Pantoprazole Sodium | 29 | $150 |
| Carvedilol | 17 | $146 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $55 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Charlottesville
- Timothy PruettCharlottesville$24K
- Josef OberholzerCharlottesville$21K
- Kenneth BraymanCharlottesville$17K
- Yazan Abu Orabi Al-AdwanCharlottesville$9K
- Danielle LadieCharlottesville$7K
- Nicolas GoldaracenaCharlottesville$5K
- Juan F Guerra CastroCharlottesville$245
- Avinash AgarwalCharlottesville$147
- Stephanie SilpeCharlottesville$131
- Seung LeeRichmond$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.